NFKB1 and atherosclerosis: Notably, PAGln’s effects are disease-context dependent: in diabetic states, it activates the cAMP/PKA/NF-κB pathway via β2AR to upregulate IL-1β/TNF-α and promote M1 macrophage polarization, accelerating atherosclerosis.